Theodore Karrison to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Theodore Karrison has written about Randomized Controlled Trials as Topic.
Connection Strength
2.337
-
Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials? Clin Trials. 2018 04; 15(2):178-188.
Score: 0.453
-
Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. J Clin Oncol. 2015 Jan 01; 33(1):36-41.
Score: 0.359
-
Evidence-based role of bevacizumab in non-small cell lung cancer. Ann Oncol. 2013 Jan; 24(1):6-9.
Score: 0.317
-
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst. 2007 Oct 03; 99(19):1455-61.
Score: 0.220
-
Continuous Bayesian adaptive randomization based on event times with covariates by Cheung et al., Statistics in Medicine 2006; 25:55-70. Stat Med. 2007 Jul 10; 26(15):3050-2; author reply 3052-4.
Score: 0.217
-
Testing the wrong hypothesis in phase II oncology trials: there is a better alternative. Clin Cancer Res. 2007 Feb 01; 13(3):781-2.
Score: 0.210
-
Scaling and interpreting treatment effects in clinical trials using restricted mean survival time. Clin Trials. 2025 Feb; 22(1):3-10.
Score: 0.175
-
A group sequential, response-adaptive design for randomized clinical trials. Control Clin Trials. 2003 Oct; 24(5):506-22.
Score: 0.167
-
Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res. 2012 Apr 15; 18(8):2309-15.
Score: 0.074
-
Surgical myomectomy followed by oral Myfembree vs standard of care (SOUL trial): Study protocol for a randomized control trial. PLoS One. 2024; 19(7):e0306053.
Score: 0.044
-
Leveraging external control data in the design and analysis of neuro-oncology trials: Pearls and perils. Neuro Oncol. 2024 05 03; 26(5):796-810.
Score: 0.043
-
The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care. Clin Pharmacol Ther. 2019 12; 106(6):1179-1183.
Score: 0.031
-
Use of Irwin's restricted mean as an index for comparing survival in different treatment groups--interpretation and power considerations. Control Clin Trials. 1997 Apr; 18(2):151-67.
Score: 0.027